| Trial ID: | L0363 |
| Source ID: | NCT00799578
|
| Associated Drug: |
Cysteamine
|
| Title: |
A Preliminary Study to Evaluate Cysteamine Therapy in Human Subjects With Non-Alcoholic Steatohepatitis (NASH)
|
| Acronym: |
--
|
| Status: |
Completed
|
| Study Results: |
Has Results
|
| Results: |
https://ClinicalTrials.gov/show/NCT00799578/results
|
| Conditions: |
Fatty Liver
|
| Interventions: |
Drug: Cysteamine
|
| Outcome Measures: |
Normalization or >50% of Serum ALT Levels From Baseline
|
| Sponsor/Collaborators: |
Joel Lavine|Raptor Pharmaceuticals Corp.|University of California, San Diego
|
| Gender: |
All
|
| Age: |
10 Years and older ?? (Child, Adult, Older Adult)
|
| Phases: |
Phase 1/Phase 2
|
| Enrollment: |
13
|
| Study Type: |
Interventional
|
| Study Designs: |
Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
|
| Start Date: |
October 2008
|
| Completion Date: |
January 2010
|
| Results First Posted: |
January 31, 2014
|
| Last Update Posted: |
January 31, 2014
|
| Locations: |
University of California, San Diego School of Medicine General Clinic Research Center, San Diego, California, United States
|
| URL: |
https://ClinicalTrials.gov/show/NCT00799578
|
